Swedish biotech Oncopeptides (Nasdaq Stockholm: ONCO) has entered into a partnership with Spanish pharmaceutical broker SD ...

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

The successful development of Frexalimab could positively impact Sanofi’s stock performance by enhancing its portfolio in the multiple sclerosis market, potentially increasing investor interest. As ...

Multiple myeloma pathogenesis is marked by incredibly complex processes that range beyond primary or acquired genetic alterations, with factors in the ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...